M. Wislez

J. Soria, D. Moro-Sibilot, M. Wislez, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Outcomes of Patients With Advanced NSCLC From the Intergroupe Francophone de Cancérologie Thoracique Biomarkers France Study by KRAS Mutation Subtypes

J. Mazières, J. Merlio, F. Escande, 2020, JTO clinical and research reports.

High expression of ligands for chemokine receptor CXCR2 in alveolar epithelial neoplasia induced by oncogenic kras.

J. Minna, I. Wistuba, D. Cody, 2006, Cancer research.

High expression of ligands for chemokine receptor CXCR2 in alveolar epithelial neoplasia induced by oncogenic kras.

J. Minna, I. Wistuba, D. Cody, 2006 .

Phase I / II study of neoadjuvant bevacizumab , erlotinib and 5-fl uorouracil with concurrent external beam radiation therapy in locally advanced rectal cancer

I. Bièche, J. Solassol, H. Blons, 2013 .

Nodular Densities after HAART Introduction in an AIDS Patient

M. Wislez, J. Cadranel, J. Naccache, 2002, Respiration.

Le patient douloureux

M. Wislez, J. Cadranel, N. Chaabane, 2018, Revue des Maladies Respiratoires Actualités.

Pulmonary Malignancies in the Immunocompromised Patient

M. Wislez, J. Cadranel, J. Naccache, 1999, Respiration.

Impact of Systematic EGFR and KRAS Mutation Evaluation on Progression-Free Survival and Overall Survival in Patients with Advanced Non–Small-Cell Lung Cancer Treated by Erlotinib in a French Prospective Cohort (ERMETIC Project—Part 2)

J. Pignon, B. Chetaille, J. Solassol, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Interstitial lung disease and anti-Jo-1 antibodies: difference between acute and gradual onset

M. Humbert, I. Tillie‐Leblond, B. Wallaert, 2007, Thorax.

[Bronchioloalveolar carcinoma and adenocarcinoma with bronchioloalveolar features: a clinico-pathological spectrum].

M. Wislez, V. Gounant, J. Cadranel, 2007, Revue des maladies respiratoires.

Hepatocyte Growth Factor Production by Neutrophils Infiltrating Bronchioloalveolar Subtype Pulmonary Adenocarcinoma : Role in Tumor Progression and Death 1

B. Milleron, B. Crestani, M. Antoine, 2003 .

Pulmonary Fibrosis in Antineutrophil Cytoplasmic Antibodies (ANCA)-Associated Vasculitis

P. Grenier, B. Housset, M. Resche-Rigon, 2014, Medicine.

Lung cancer and interstitial lung disease: a literature review.

M. Antoine, M. Wislez, C. Chouaid, 2018, Journal of thoracic disease.

Blood vessel invasion is a major feature and a factor of poor prognosis in sarcomatoid carcinoma of the lung.

M. Antoine, M. Wislez, M. Beau-Faller, 2014, Lung cancer.

Upregulation of bronchioloalveolar carcinoma-derived C-X-C chemokines by tumor infiltrating inflammatory cells

B. Milleron, M. Antoine, M. Wislez, 2003, Inflammation Research.

Tumor-derived granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor prolong the survival of neutrophils infiltrating bronchoalveolar subtype pulmonary adenocarcinoma.

B. Milleron, M. Antoine, M. Wislez, 2001, The American journal of pathology.

Predictive Value of Soluble PD-1, PD-L1, VEGFA, CD40 Ligand and CD44 for Nivolumab Therapy in Advanced Non-Small Cell Lung Cancer: A Case-Control Study

K. Leroy, H. Blons, F. Goldwasser, 2020, Cancers.

Is there an Exposure–Response Relationship for Nivolumab in Real-World NSCLC Patients?

E. Ollier, F. Goldwasser, D. Damotte, 2019, Cancers.

Clinical characteristics and prognostic factors of pulmonary MALT lymphoma

R. Borie, H. Mal, B. Crestani, 2009, European Respiratory Journal.

quels patients âgés ? Cancers bronchopulmonaires non à petites cellules Non-small-cell lung cancer

B. Milleron, M. Wislez, L. Belmont, 2008 .

SMARCA4-deficient lung carcinoma is an aggressive tumor highly infiltrated by FOXP3+ cells and neutrophils.

L. Fournel, F. Petitprez, I. Cremer, 2022, Lung cancer.

Mutations at the splice sites of exon 14 of MET gene: a new target for sarcomatoid carcinomas?

M. Wislez, A. Lemoine, A. Cortot, 2016, Annals of translational medicine.

Phosphatidylinositol 3-Kinase Mediates Bronchioalveolar Stem Cell Expansion in Mouse Models of Oncogenic K-ras-Induced Lung Cancer

I. Wistuba, J. Kurie, G. Powis, 2008, PloS one.

Phase I/II study of neoadjuvant bevacizumab, erlotinib and 5-fluorouracil with concurrent external beam radiation therapy in locally advanced rectal cancer

I. Bièche, J. Solassol, H. Blons, 2013 .

[Perioperative therapies in surgical non N2 non-small cell lung cancer].

M. Wislez, J. Assouad, J. Cadranel, 2017, Bulletin du cancer.

NRG1 fusion in a French cohort of invasive mucinous lung adenocarcinoma

M. Antoine, M. Wislez, J. Cadranel, 2016, Cancer medicine.

Release of metal particles from needles used for transbronchial needle aspiration.

V. Ninane, J. Bernaudin, M. Wislez, 2011, Chest.

Pemetrexed-induced pneumonitis: a case report.

J. Soria, Y. Loriot, M. Wislez, 2009, Clinical lung cancer.

Skin Toxicities Compromise Prolonged Pemetrexed Treatment

B. Milleron, M. Wislez, V. Gounant, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Non-mucinous and mucinous subtypes of adenocarcinoma with bronchioloalveolar carcinoma features differ by biomarker expression and in the response to gefitinib.

M. Antoine, M. Wislez, E. Longchampt, 2010, Lung cancer.

IFCT0401-bio phase II trial: Gefitinib administered as 1st-line in non-resectable adenocarcinoma with bronchioloalveolar carcinoma features (ADC-BAC)—Predictive biomarkers of efficacy and survival

E. Brambilla, F. Coulet, M. Antoine, 2008 .

IFCT0401-bio trial: Predictive biological markers for disease control (DC) of patients with non-resectable, adenocarcinoma with bronchioloalveolar carcinoma features (ADC-BAC) treated with gefitinib

G. Zalcman, F. Coulet, P. Souquet, 2007 .

c‐MET Overexpression as a Poor Predictor of MET Amplifications or Exon 14 Mutations in Lung Sarcomatoid Carcinomas

N. Girard, S. Lantuejoul, J. Mazières, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Anaplastic lymphoma kinase (ALK) rearrangement is a rare feature in advanced non-small cell lung cancer (NSCLC), occurring in around 5% of the patients (1). This oncogenic addiction is more frequent in no/light-smokers, in thyroid transcription factor-1 (TTF1)-positive adenocarcinoma, with cribrifor

M. Wislez, E. G. Leprieur, 2018 .

High expression of ErbB family members and their ligands in lung adenocarcinomas that are sensitive to inhibition of epidermal growth factor receptor.

R. Price, J. Minna, Jie Zhang, 2005, Cancer research.

Proposals for managing patients with thoracic malignancies during COVID-19 pandemic

N. Girard, J. Mazières, G. Zalcman, 2020, Respiratory Medicine and Research.

A Prospective Study of 273 BAL Procedures

A. Flahault, M. Antoine, M. Wislez, 2015 .

Clonality and phenotyping analysis of alveolar lymphocytes is suggestive of pulmonary MALT lymphoma.

R. Borie, B. Crestani, M. Antoine, 2011, Respiratory medicine.

Impact of randomized clinical trials on clinical practice regarding treatment of lung cancer.

B. Milleron, M. Wislez, I. Debrix, 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Inhibition of mammalian target of rapamycin reverses alveolar epithelial neoplasia induced by oncogenic K-ras.

R. Price, I. Wistuba, D. Cody, 2005, Cancer research.

Pulmonary mucosa-associated lymphoid tissue lymphoma revisited

C. Copie-Bergman, R. Borie, M. Antoine, 2016, European Respiratory Journal.

B. Milleron, O. Molinier, G. Zalcman, 2016, European Respiratory Journal.

Organizing Pneumonia Related to Common Variable Immunodeficiency

É. Oksenhendler, M. Sibony, M. Wislez, 2000, Respiration.

Organizing pneumonia related to common variable immunodeficiency. case report and literature review.

É. Oksenhendler, M. Sibony, M. Wislez, 2000, Respiration; international review of thoracic diseases.

EGFR and KRAS mutation status in non-small-cell lung cancer occurring in HIV-infected patients.

M. Antoine, M. Wislez, C. Chouaid, 2016, Lung cancer.

Nonsmall cell lung cancer from HIV-infected patients expressed programmed cell death-ligand 1 with marked inflammatory infiltrates

C. Hamard, M. Antoine, M. Wislez, 2017, AIDS.

Does Very Poor Performance Status Systematically Preclude Single Agent Anti-PD-1 Immunotherapy? A Multicenter Study of 35 Consecutive Patients

A. Cazes, O. Molinier, J. Trédaniel, 2021, Cancers.

Molecular classification of pulmonary sarcomatoid carcinomas suggests new therapeutic opportunities

P. Laurent-Puig, H. Blons, M. Antoine, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Life-threatening hemoptysis in adults with community-acquired pneumonia due to Panton-Valentine leukocidin-secreting Staphylococcus aureus

M. Antoine, M. Wislez, J. Etienne, 2003, Intensive Care Medicine.

Manifestations respiratoires au cours du déficit immunitaire commun variable de l'adulte

M. Wislez, J. Cadranel, D. Bouvry, 2003 .

Chest CT scan plus x-ray versus chest x-ray for the follow-up of completely resected non-small-cell lung cancer (IFCT-0302): a multicentre, open-label, randomised, phase 3 trial.

N. Girard, E. Devin, J. Muir, 2022, The Lancet. Oncology.

Influence of the SARS-CoV-2 outbreak on management and prognosis of new lung cancer cases, a retrospective multicentre real-life cohort study

C. Tournigand, L. Zelek, G. Zalcman, 2022, European Journal of Cancer.

[Therapeutic management of poorly differentiated neuroendocrine lung tumors and neuroendocrine carcinomas of the digestive system].

P. Hammel, M. Wislez, M. Svrcek, 2016, Bulletin du cancer.

Sequential or combined immune checkpoint inhibitors and targeted therapy: Navigating uncharted waters.

M. Wislez, K. El Husseini, 2021, Respiratory medicine and research.

Primary pulmonary lymphoma

M. Antoine, M. Wislez, J. Cadranel, 1997, European Respiratory Journal.

M. Antoine, M. Wislez, M. Mary-Krause, 1998, American journal of respiratory and critical care medicine.

A. Flahault, M. Antoine, M. Wislez, 2001, Chest.

Immunodynamics of explanted human tumors for immuno‐oncology

L. Zitvogel, G. Kroemer, E. Fadel, 2020, EMBO molecular medicine.

Improvement of symptomatic human immunodeficiency virus-related lymphoid interstitial pneumonia in patients receiving highly active antiretroviral therapy.

E. Bergot, M. Wislez, J. Cadranel, 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Impact of the COVID-19 pandemic on the management of cancer patients: the experience of the cancer outpatients department of a university hospital in Paris.

F. Goldwasser, C. Tlemsani, M. Wislez, 2021, Clinical medicine.

Characterization of lung cancers in patients with BRCA germline variants: A multicenter series.

S. Culine, G. Zalcman, F. Coulet, 2022, Lung cancer.

Brigatinib for Pretreated, ALK-Positive, Advanced Non-Small-Cell Lung Cancers: Long-Term Follow-Up and Focus on Post-Brigatinib Lorlatinib Efficacy in the Multicenter, Real-World BrigALK2 Study

D. Planchard, F. Guisier, M. Wislez, 2022, Cancers.

040 mTOR inhibition reverses alveolar epithelial neoplasia induced by oncogenic K-ras

I. Wistuba, D. Cody, J. Kurie, 2005 .

Crizotinib in patients with advanced ROS1-rearranged non-small cell lung cancer (NSCLC). Preliminary results of the ACSé phase II trial.

G. Ferretti, S. Lantuejoul, G. Vassal, 2015 .

Immunotherapy’s new challenge: identification of predictive biomarkers for tumor response

M. Antoine, M. Wislez, A. Ruppert, 2017 .

Exposure–Response Analysis of Osimertinib in Patients with Advanced Non-Small-Cell Lung Cancer

F. Goldwasser, C. Csajka, M. Wislez, 2022, Pharmaceutics.

Histomolecular Resistance Mechanisms to First-Line Osimertinib in EGFR-Mutated Advanced Non-Small Cell Lung Cancer: A Multicentric Retrospective French Study

J. Trédaniel, M. Wislez, V. Gounant, 2022, Targeted Oncology.

Lung CAncer SCreening in French women using low-dose CT and Artificial intelligence for DEtection: the CASCADE study protocol

M. Revel, I. Durand-zaleski, G. Chassagnon, 2022, BMJ Open.

Short-term and long-term outcomes of patients with lung cancer and life-threatening complications.

L. Fournel, J. Mira, F. Pène, 2021, Chest.

Risk of scleroderma according to the type of immune checkpoint inhibitors.

L. Mouthon, F. Goupil, J. Hadjadj, 2020, Autoimmunity reviews.

Cost-effectiveness of KRAS, EGFR and ALK testing for decision making in advanced nonsmall cell lung carcinoma: the French IFCT-PREDICT.amm study

Franck Morin, Patrick Merle, Pascal Auquier, 2018, European Respiratory Journal.

Sarcoidosis in HIV-infected patients in the era of highly active antiretroviral therapy.

M. Wislez, D. Valeyre, F. Blanc, 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Sarcoid-like pulmonary disorder in human immunodeficiency virus-infected patients receiving antiretroviral therapy.

É. Oksenhendler, M. Antoine, M. Wislez, 1999, American journal of respiratory and critical care medicine.

Lung cancer in HIV infected patients: facts, questions and challenges

B. Milleron, M. Wislez, D. Garfield, 2006, Thorax.

Lung cancer, a new challenge in the HIV-infected population.

B. Milleron, M. Antoine, M. Wislez, 2006, Lung cancer.

B. Milleron, M. Wislez, D. Garfield, 2006 .

[Lung cancer in HIV-infected patients].

M. Antoine, M. Wislez, J. Cadranel, 2018, Bulletin du cancer.

Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures.

E. Tartour, W. Fridman, D. Heudes, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The Bronchioloalveolar Carcinoma and Peripheral Adenocarcinoma Spectrum of Diseases

F. Hirsch, W. Franklin, M. Wislez, 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Clinical characteristics of pneumonic-type adenocarcinoma of the lung.

B. Milleron, M. Antoine, M. Wislez, 2003, Chest.

Non-severe eosinophilic granulomatosis with polyangiitis: long-term outcomes after remission-induction trial.

G. Baron, P. Ravaud, B. Bonnotte, 2019, Rheumatology.

Updated Prognostic Factors in Localized NSCLC

L. Fournel, H. Blons, S. Garinet, 2022, Cancers.

Clinicopathologic Features and Response to Therapy of NRG1 Fusion–Driven Lung Cancers: The eNRGy1 Global Multicenter Registry

A. Drilon, M. Okada, S. Ou, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort.

F. Cappuzzo, S. Peters, J. Mazières, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives.

S. Peters, E. Felip, J. Mazières, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Lymphoproliferative Disorders of the Lung

R. Borie, M. Antoine, M. Wislez, 2017, Respiration.

[SMARCA4-deficient thoracic tumors: A new entity].

L. Fournel, K. Leroy, M. Alifano, 2020, Bulletin du cancer.

Intratumoral heterogeneity generated by Notch signaling promotes small cell lung cancer

K. Garcia, M. Fischer, J. Sage, 2017, Nature.

TP53, STK11, and EGFR Mutations Predict Tumor Immune Profile and the Response to Anti–PD-1 in Lung Adenocarcinoma

P. Laurent-Puig, I. Cremer, K. Leroy, 2018, Clinical Cancer Research.

Composite biomarkers defined by multiparametric immunofluorescence analysis identify ALK-positive adenocarcinoma as a potential target for immunotherapy

P. Laurent-Puig, E. Tartour, H. Blons, 2017, Oncoimmunology.

EGFR Exon 20 Insertion in Metastatic Non-Small-Cell Lung Cancer: Survival and Clinical Efficacy of EGFR Tyrosine-Kinase Inhibitor and Chemotherapy

K. Leroy, X. Mignard, M. Wislez, 2021, Cancers.

The PI3K/AKT pathway promotes gefitinib resistance in mutant KRAS lung adenocarcinoma by a deacetylase‐dependent mechanism

E. Brambilla, J. Coll, A. Hurbin, 2014, International journal of cancer.

c-Jun N-terminal kinase is activated in non-small-cell lung cancer and promotes neoplastic transformation in human bronchial epithelial cells

J. Pollack, J. Minna, I. Wistuba, 2007, Oncogene.

Regulator of telomere length 1 (RTEL1) mutations are associated with heterogeneous pulmonary and extra-pulmonary phenotypes

P. Revy, P. Dieudé, A. Cazes, 2019, European Respiratory Journal.

Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network.

J-L Pretet, I. Bièche, J. Solassol, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[MET exon 14 splicing sites mutations: A new therapeutic opportunity in lung cancer].

A. Furlan, M. Wislez, D. Tulasne, 2018, Revue des maladies respiratoires.

Exon 14 Deleted MET Receptor as a New Biomarker and Target in Cancers

A. Furlan, M. Wislez, D. Tulasne, 2017, Journal of the National Cancer Institute.

Lung Cancer and Its Microenvironment

J. Kurie, M. Wislez, J. Cadranel, 2022 .

The intersection of EGFR and the Ras signaling pathway

J. Kurie, M. Wislez, 2008 .

[A simple view on lung cancer biology: the MET pathway].

M. Antoine, M. Wislez, J. Cadranel, 2011, Revue des maladies respiratoires.

[A simple view on lung cancer biology: the MET pathway].

M. Wislez, V. Gounant, J. Cadranel, 2011, Revue des maladies respiratoires.

Sarcomatoid lung carcinomas show high levels of programmed death ligand-1 (PD-L1) and strong immune-cell infiltration by TCD3 cells and macrophages.

C. Hamard, M. Antoine, M. Wislez, 2016, Lung cancer.

Efficacy of First-Line Chemotherapy in Patients with Advanced Lung Sarcomatoid Carcinoma

N. Girard, A. Cazes, J. Mazières, 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Lepidic predominant adenocarcinoma and invasive mucinous adenocarcinoma of the lung exhibit specific mucin expression in relation with oncogenic drivers.

I. van Seuningen, M. Antoine, M. Wislez, 2017, Lung cancer.

[IHC, FISH, CISH, NGS in non-small cell lung cancer: What changes in the biomarker era?]

P. Laurent-Puig, K. Leroy, H. Blons, 2018, Revue de pneumologie clinique.

Therapeutic strategy for advanced EGFR mutant non-small-cell lung carcinoma.

M. Wislez, M. Beau-Faller, J. Cadranel, 2013, Critical reviews in oncology/hematology.

Clinical and molecular features in patients with advanced non-small-cell lung carcinoma refractory to first-line platinum-based chemotherapy.

B. Milleron, M. Antoine, M. Wislez, 2013, Lung cancer.

Customized adjuvant phase II trial in patients with non-small-cell lung cancer: IFCT-0801 TASTE.

J. Soria, J. Mazières, G. Zalcman, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Immune-Checkpoint Inhibitors for Malignant Pleural Mesothelioma: A French, Multicenter, Retrospective Real-World Study

M. Wislez, A. Scherpereel, C. Gauvain, 2022, Cancers.

A selective small molecule inhibitor of c-Met, PHA-665752, reverses lung premalignancy induced by mutant K-ras

Lin Ji, Yanan Yang, Ignacio Wistuba, 2008, Molecular Cancer Therapeutics.

Hepatocyte growth factor production by neutrophils infiltrating bronchioloalveolar subtype pulmonary adenocarcinoma: role in tumor progression and death.

B. Milleron, B. Crestani, M. Antoine, 2003, Cancer research.

High TUBB3 Expression, an Independent Prognostic Marker in Patients with Early Non–Small Cell Lung Cancer Treated by Preoperative Chemotherapy, Is Regulated by K-Ras Signaling Pathway

E. Brambilla, J. Camonis, J. Pujol, 2012, Molecular Cancer Therapeutics.

Molecular Medicine in Practice High TUBB 3 Expression , an Independent Prognostic Marker in Patients with Early Non – Small Cell Lung Cancer Treated by Preoperative Chemotherapy , Is Regulated by KRas Signaling Pathway

E. Brambilla, J. Camonis, J. Pujol, 2012 .

Factors associated with long‐term survival of patients with advanced non‐small cell lung cancer

B. Milleron, M. Wislez, V. Gounant, 2012, Respirology.

[American Society of Clinical Oncology (ASCO) 2011 essential data: the editorial board of the Bulletin du Cancer point of view].

J. Blay, J. Thariat, J. Bay, 2011, Bulletin du cancer.

[American Society of Clinical Oncology (ASCO) 2011 essential data: the editorial board of the Bulletin du Cancer point of view].

J. Blay, J. Thariat, J. Bay, 2011, Bulletin du cancer.

French Intensive Care Society, International congress – Réanimation 2016

Paul P. Tallon, Stéphane Huot, B. Souweine, 2016, Annals of Intensive Care.

Crizotinib for ROS 1-rearranged non-small cell lung cancer patients

M. Antoine, M. Wislez, J. Cadranel, 2019 .

[Crizotinib for ROS1-rearranged non-small cell lung cancer patients].

M. Antoine, M. Wislez, J. Cadranel, 2017, Bulletin du cancer.

Insulin‐like growth factor‐1 receptor inhibition overcomes gefitinib resistance in mucinous lung adenocarcinoma

E. Brambilla, F. de Fraipont, D. Moro-Sibilot, 2011, The Journal of pathology.

Outcome of EGFR-mutated NSCLC patients with MET-driven resistance to EGFR tyrosine kinase inhibitors

N. Girard, J. Mazières, D. Moro-Sibilot, 2017, Oncotarget.

Dependence on Phosphoinositide 3-Kinase and RAS-RAF Pathways Drive the Activity of RAF265, a Novel RAF/VEGFR2 Inhibitor, and RAD001 (Everolimus) in Combination

J. Bourhis, J. Calderaro, J. Soria, 2010, Molecular Cancer Therapeutics.

[Modalities of use of ceritinib (Zykadia™), a 2nd generation ALK inhibitor, in advanced stage non-small cell lung cancer].

M. Wislez, M. Wislez, V. Fallet, 2015, Bulletin du cancer.

Prospective screening for ALK: clinical features and outcome according to ALK status.

M. Antoine, M. Wislez, T. Chinet, 2014, European journal of cancer.

Nivolumab increases pulmonary artery pressure in patients treated for non-small cell lung cancer

L. Fournel, F. Goldwasser, F. Batteux, 2020, Cancer Chemotherapy and Pharmacology.

Brigatinib in patients with ALK-positive advanced non-small-cell lung cancer pretreated with sequential ALK inhibitors: A multicentric real-world study (BRIGALK study).

D. Planchard, F. Guisier, M. Wislez, 2019, Lung cancer.

[Smoking cessation therapy in thoracic oncology].

M. Wislez, V. Gounant, J. Cadranel, 2013, Revue des maladies respiratoires.

Spotlight on crizotinib in the first-line treatment of ALK-positive advanced non-small-cell lung cancer: patients selection and perspectives

M. Wislez, J. Cadranel, V. Fallet, 2016, Lung Cancer.

Real-life effectiveness of erlotinib as second-line treatment of stage IIIB/IV squamous non-small cell lung cancer: Results of the PEPiTA observational study.

N. Girard, O. Molinier, P. Souquet, 2016, Lung cancer.

Factors associated with early progression of non-small-cell lung cancer treated by epidermal growth factor receptor tyrosine-kinase inhibitors

M. Antoine, M. Wislez, J. Cadranel, 2014, Cancer medicine.

The rising challenge of oncogene addiction in lung cancer.

M. Wislez, K. El Husseini, 2021, Bulletin du cancer.

Mutations in COPA lead to abnormal trafficking of STING to the Golgi and interferon signaling

T. Molina, Y. Crow, J. Marsh, 2020, The Journal of experimental medicine.

Lung carcinoid tumors with Diffuse Idiopathic Pulmonary NeuroEndocrine Cell Hyperplasia (DIPNECH) exhibit pejorative pathological features.

L. Fournel, G. Chassagnon, M. Alifano, 2021, Lung cancer.

Circulating tumor DNA in advanced non-small-cell lung cancer patients with HIV is associated with shorter overall survival: Results from a Phase II trial (IFCT-1001 CHIVA).

P. Laurent-Puig, J. Mazières, H. Blons, 2021, Lung cancer.

Cancer du poumon et infection par le Virus de l’Immunodéficience Humaine

M. Wislez, J. Cadranel, L. Belmont, 2014 .

Acute respiratory failure following HAART introduction in patients treated for Pneumocystis carinii pneumonia.

E. Bergot, M. Antoine, M. Wislez, 2001, American journal of respiratory and critical care medicine.

Effect of highly active antiretroviral therapy on survival of HIV infected patients with non-small-cell lung cancer.

B. Milleron, M. Wislez, G. Pialoux, 2009, Lung cancer.

[Lung cancer in HIV-infected patients].

M. Antoine, M. Wislez, J. Cadranel, 2017, Bulletin du cancer.

The homeobox gene EMX2 is a prognostic and predictive marker in malignant pleural mesothelioma.

D. Jablons, M. Wislez, J. Okamoto, 2014, Lung cancer.

LBA52 Tepotinib + osimertinib for EGFRm NSCLC with MET amplification (METamp) after progression on first-line (1L) osimertinib: Initial results from the INSIGHT 2 study

C. Dooms, F. de Marinis, J. Mazières, 2022, Annals of Oncology.

Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial.

G. Ferretti, G. Vassal, J. Mazières, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Pulmonary mucosa-associated lymphoid tissue lymphoma revisited

C. Copie-Bergman, R. Borie, M. Antoine, 2016, European Respiratory Journal.

Pulmonary MALT Lymphoma: Clinical, Molecular and Therapeutic Aspects

R. Borie, M. Antoine, M. Wislez, 2011 .

Efficacy of Immune Checkpoint Inhibitors in Lung Sarcomatoid Carcinoma.

O. Molinier, J. Mazières, K. Leroy, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Calpain 1 in bronchoalveolar lavage fluid is associated with poor prognosis in lepidic predominant pulmonary adenocarcinoma.

M. Antoine, M. Wislez, L. Baud, 2019, Bulletin du cancer.

[Following communications made at American Society of Clinical Oncology 2010, what will change our practice? The point of view of the editorial board of Bulletin du Cancer].

J. Blay, M. Wislez, C. Massard, 2010, Bulletin du cancer.

Risk of lung cancer among women in relation to lifetime history of tobacco smoking: a population-based case-control study in France (the WELCA study)

P. Guénel, P. Laurent-Puig, H. Blons, 2021, BMC Cancer.

Sleep Traits, Night Shift Work and Lung Cancer Risk among Women: Results from a Population-Based Case-Control Study in France (The WELCA Study)

P. Guénel, P. Laurent-Puig, H. Blons, 2022, International journal of environmental research and public health.

Is there a specific phenotype associated with the different subtypes of KRAS mutations in patients with advanced non-small-cell lung cancers?

M. Antoine, M. Wislez, E. Rouleau, 2015, Lung cancer.

Development and validation of a host-dependent, PDL1-independent, biomarker to predict 6-month progression-free survival in metastatic non-small cell lung cancer (mNSCLC) patients treated with anti-PD1 immune checkpoint inhibitors (ICI) in the CERTIM Cohort: The ELY study

F. Goldwasser, C. Gervais, M. Alifano, 2021, EBioMedicine.

Fluorine-18 Fluorodeoxyglucose with Positron Emission Tomography Revealed Bone Marrow Involvement in Sarcoidosis Patients with Anaemia

M. Sibony, J. Talbot, M. Wislez, 2009, Respiration.

Secondary resistance to erlotinib: acquired T790M mutation and small-cell lung cancer transformation in the same patient.

M. Antoine, M. Wislez, J. Cadranel, 2012, Journal of Thoracic Oncology.

Lymphoma of pulmonary mucosa-associated lymphoid tissue: CT scan findings and pathological correlations.

B. Milleron, M. Antoine, M. Wislez, 1999, The European respiratory journal.

SRC-family kinases are activated in non-small cell lung cancer and promote the survival of epidermal growth factor receptor-dependent cell lines.

Jie Zhang, I. Wistuba, J. Kurie, 2007, The American journal of pathology.

Pro-tumoural CXCL10/CXCR3-A autocrine loop in invasive mucinous lung adenocarcinoma

M. Antoine, M. Wislez, J. Cadranel, 2017, ERJ Open Research.

Gefitinib-associated Propionibacterium acnes pleural empyema.

M. Wislez, J. Cadranel, N. de Prost, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Relevance of Detection of Mechanisms of Resistance to ALK Inhibitors in ALK-Rearranged NSCLC in Routine Practice.

M. Copin, F. Escande, M. Wislez, 2019, Clinical lung cancer.

Spectrum of CD4 to CD8 T-cell ratios in lymphocytic alveolitis associated with methotrexate-induced pneumonitis.

J. Bernaudin, M. Wislez, H. Prigent, 2001, American journal of respiratory and critical care medicine.

CONTINUING EDUCATION PROGRAM : FOCUS . . . 2014 update on non-small cell lung cancer ( excluding diagnosis )

B. Milleron, M. Antoine, M. Wislez, 2014 .

Molecular biology, genomics, and proteomics in bronchioloalveolar carcinoma.

D. Beer, I. Wistuba, N. Saijo, 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Reaching multidisciplinary consensus on the management of non-bulky/non-infiltrative stage IIIA N2 non-small cell lung cancer.

P. Giraud, M. Alifano, M. Wislez, 2023, Lung cancer.

Real-life efficacy of osimertinib in pretreated patients with advanced non-small cell lung cancer harboring EGFR T790M mutation.

D. Planchard, F. Guisier, M. Wislez, 2019, Lung cancer.

Pattern of Lung Cancer in Turkey, 1994–1998

H. Kume, Y. Takeshima, N. Kohno, 2002, Respiration.

Proposal for a Combined Histomolecular Algorithm to Distinguish Multiple Primary Adenocarcinomas from Intrapulmonary Metastasis in Patients with Multiple Lung Tumors

L. Fournel, P. Laurent-Puig, I. Cremer, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Hypermetabolism is an independent prognostic factor of survival in metastatic non-small cell lung cancer patients.

L. Fournel, F. Goldwasser, C. Tlemsani, 2020, Clinical nutrition.

The impact of body composition parameters on severe toxicity of nivolumab.

F. Goldwasser, C. Gervais, M. Wislez, 2019, European journal of cancer.

Imaging of Hereditary Hemorrhagic Telangiectasia

M. Wislez, A. Khalil, C. Nedelcu, 2008, CardioVascular and Interventional Radiology.

Erlotinib versus carboplatin and paclitaxel in advanced lepidic adenocarcinoma: IFCT-0504

G. Zalcman, D. Moro-Sibilot, F. Barlesi, 2015, European Respiratory Journal.

Changes in the Pattern of Respiratory Diseases Necessitating Hospitalization of HIV-infectedPatients Since the Advent of Highly Active Antiretroviral Therapy

E. Bergot, M. Wislez, P. Rufat, 2004, Lung.

Predictive factors associated with pemetrexed acute toxicity

F. Goldwasser, M. Wislez, A. Jouinot, 2023, European Journal of Clinical Pharmacology.

Prise en charge thérapeutique des adénocarcinomes de type bronchiolo-alvéolaires étendus : chimiothérapie ou inhibiteurs de la tyrosine kinase du récepteur de l'epidermal growth factor ?

B. Milleron, M. Antoine, M. Wislez, 2007 .

1273OResults of the phase III IFCT-0302 trial assessing minimal versus CT-scan-based follow-up for completely resected non-small cell lung cancer (NSCLC)

E. Devin, J. Lafitte, J. Trédaniel, 2017 .

Neoadjuvant durvalumab for resectable non-small-cell lung cancer (NSCLC): results from a multicenter study (IFCT-1601 IONESCO)

B. Milleron, F. Le Pimpec Barthès, O. Molinier, 2022, Journal for ImmunoTherapy of Cancer.

Optimiser le bilan d'extension locorégional

M. Antoine, M. Wislez, A. Lavolé, 2015 .

Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment: A French nationwide cohort study (GCO-002 CACOVID-19)

N. Magné, B. Chauffert, F. Ducray, 2020, European Journal of Cancer.

1214O Neoadjuvant durvalumab in resectable non-small cell lung cancer (NSCLC): Preliminary results from a multicenter study (IFCT-1601 IONESCO)

B. Milleron, O. Molinier, J. Mazières, 2020 .

1151MO Pathological response is an independent factor of overall survival and disease-free survival after neoadjuvant durvalumab in resectable non-small cell lung cancer (NSCLC) in the IFCT-1601 IONESCO phase II trial

B. Milleron, F. Le Pimpec Barthès, J. Mazières, 2021, Annals of Oncology.

[IoNESCO trial: Immune neoajuvant therapy in early stage non-small cell lung cancer].

B. Milleron, G. Zalcman, D. Moro-Sibilot, 2018, Revue des maladies respiratoires.

Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial.

G. Ferretti, G. Vassal, J. Mazières, 2019 .

High-throughput somatic mutation profiling in pulmonary sarcomatoid carcinomas using the LungCarta™ Panel: exploring therapeutic targets.

N. Girard, S. Lantuejoul, J. Mazières, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Expression of TLR9 in tumor‐infiltrating mononuclear cells enhances angiogenesis and is associated with a worse survival in lung cancer

J. Kurie, M. Antoine, M. Wislez, 2014, International journal of cancer.

Chemoradiotherapy efficacy is predicted by intra-tumour CD8+/FoxP3+ double positive T cell density in locally advanced N2 non-small-cell lung carcinoma.

L. Fournel, P. Giraud, I. Cremer, 2020, European journal of cancer.

Women Epidemiology Lung Cancer (WELCA) study: reproductive, hormonal, occupational risk factors and biobank

J. Pastre, P. Laurent-Puig, M. Neri, 2017, BMC Public Health.

VEGF neutralizing aerosol therapy in primary pulmonary adenocarcinoma with K-ras activating-mutations

E. Lemarié, N. Heuzé-Vourc’h, M. Wislez, 2014, mAbs.

Role of atmospheric pollution on the natural history of idiopathic pulmonary fibrosis

I. Annesi-Maesano, V. Cottin, G. Prévot, 2017, Thorax.

EGFR tyrosine kinase inhibitors versus chemotherapy in EGFR wild-type pre-treated advanced nonsmall cell lung cancer in daily practice

J. Mosser, J. Mazières, G. Zalcman, 2017, European Respiratory Journal.

Crizotinib Associated with Ground-Glass Opacity Predominant Pattern Interstitial Lung Disease: A Retrospective Observational Cohort Study with a Systematic Literature Review

M. Antoine, M. Wislez, V. Gounant, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Targeted Therapy for Older Patients with Non-Small Cell Lung Cancer: Systematic Review and Guidelines from the French Society of Geriatric Oncology (SoFOG) and the French-Language Society of Pulmonology (SPLF)/French-Language Oncology Group (GOLF)

N. Girard, S. Mathoulin-Pélissier, M. Wislez, 2022, Cancers.

[Pulmonary sarcomatoid carcinoma].

M. Antoine, M. Wislez, M. Wislez, 2012, Bulletin du cancer.

[Pulmonary malt lymphoma].

R. Borie, M. Antoine, M. Wislez, 2014, Bulletin du Cancer.

Sonic Hedgehog Pathway Activation Is Associated With Resistance to Platinum-Based Chemotherapy in Advanced Non-Small-Cell Lung Carcinoma.

M. Antoine, M. Wislez, J. Cadranel, 2016, Clinical lung cancer.

[Respiratory manifestations of common variable immunodeficiency in adults].

M. Wislez, J. Cadranel, D. Bouvry, 2003, Revue des maladies respiratoires.

The impact of intracytoplasmic mucin in lung adenocarcinoma with pneumonic radiological presentation.

M. Antoine, M. Wislez, J. Cadranel, 2014, Lung Cancer.

Efficacy of next treatment received after nivolumab progression in patients with advanced nonsmall cell lung cancer

J. Trédaniel, M. Wislez, C. Chouaid, 2018, ERJ Open Research.

Hypodermal ‘pseudo‐cellulitic’ infiltrate heralding Churg and Strauss syndrome flares in two patients

M. Wislez, S. Aractingi, J. Cadranel, 2008, Journal of the European Academy of Dermatology and Venereology : JEADV.

[News about targeted therapies in non-small-cell lung cancer in 2015 (except immuno-therapy)].

C. Hamard, M. Antoine, M. Wislez, 2016, Annales de pathologie.

Rapid and Sensitive p53 Alteration Analysis in Biopsies from Lung Cancer Patients Using a Functional Assay and A Universal Oligonucleotide Array

F. Barany, B. Milleron, T. Soussi, 2004, Clinical Cancer Research.

[Pulmonary sarcomatoid carcinoma].

C. Hamard, M. Antoine, M. Wislez, 2016, Annales de pathologie.

OA 16.03 Recurrences and 2nd Primary Cancers in the IFCT-0302 Trial Assessing a CT-Scan-Based Follow-Up after Lung Cancer Surgery

N. Girard, J. Lafitte, J. Muir, 2017 .

Murine Lung Tumor Measurement Using Respiratory-Gated Micro-Computed Tomography

B Nebiyou Bekele, Dianna D Cody, Roger E Price, 2005, Investigative radiology.

Eﬀicacy of next treatment received after nivolumab progression in patients with advanced nonsmall cell lung cancer

J. Trédaniel, M. Wislez, E. Giroux-Leprieur, 2023 .

Primary pulmonary lymphoma

B. Milleron, J. Bernaudin, M. Antoine, 2002, European Respiratory Journal.

[AIDS and the lung at the era of highly active antiretroviral therapies].

M. Wislez, J. Cadranel, C. Mayaud, 2002, Revue des maladies respiratoires.

Postoperative follow-up of lung cancer: Randomized trial comparing two follow-up programs in completely resected non-small cell lung cancer (IFCT-0302).

E. Devin, J. Lafitte, J. Trédaniel, 2012 .

Human RNA polymerase II associated factor 1 complex promotes tumorigenesis by activating c-MYC transcription in non-small cell lung cancer.

Mu Hu, Lei Wang, Huaiyin Shi, 2015, Biochemical and biophysical research communications.

c‐MET Overexpression as a Poor Predictor of MET Amplifications or Exon 14 Mutations in Lung Sarcomatoid Carcinomas

N. Girard, S. Lantuejoul, J. Mazières, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[A new perspective in the treatment of non-small-cell lung cancer (NSCLC). Role of afatinib: An oral and irreversible ErbB family blocker].

D. Moro-Sibilot, F. Scotté, M. Wislez, 2014, Bulletin du cancer.

Alectinib in untreated anaplastic lymphoma kinase-positive non-small cell lung cancer.

X. Mignard, M. Wislez, A. Ruppert, 2017, Annals of translational medicine.

Intratumoral Epiregulin Is a Marker of Advanced Disease in Non–Small Cell Lung Cancer Patients and Confers Invasive Properties on EGFR-Mutant Cells

Jie Zhang, I. Wistuba, J. Kurie, 2008, Cancer Prevention Research.

Sensitivity to chemotherapy/tyrosine kinase inhibitors of mucinous lepidic adenocarcinoma should be tested in a phase III trial?

G. Zalcman, M. Wislez, F. Morin, 2016, European Respiratory Journal.

VEGF neutralizing aerosol therapy in primary pulmonary adenocarcinoma with K-ras activating-mutations

E. Lemarié, N. Heuzé-Vourc’h, M. Wislez, 2014, mAbs.

The impact of intracytoplasmic mucin in lung adenocarcinoma with pneumonic radiological presentation.

M. Antoine, M. Wislez, J. Cadranel, 2014, Lung cancer.